Bull case
Progyny is supported by a differentiated fertility and family-building platform that combines Smart Cycles, a curated clinician network, integrated pharmacy access, and high-touch care advocacy, which management and analysts say is difficult to replicate. Its fundamentals are reinforced by best-in-class retention above 99%, win rates above 50% in competitive deals, approximately 7 million covered lives served out of roughly 105 million self-insured lives, and 1Q26 results that beat consensus on revenue and EBITDA while active clients rose to 595 and average membership reached 7.2 million. The outlook is further strengthened by expanding addressable markets through Progyny Select and payer partnerships, improving gross margin to 27.2%, and 2026 guidance increases to $1.365 billion to $1.405 billion of revenue and $232 million to $244 million of EBITDA.